Navigation Links
Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Date:6/4/2008

PRINCETON, N.J., June 4 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Needham & Co. Biotechnology and Medical Technology Conference being held from June 11-12, 2008 at the New York Palace Hotel in New York, NY. Schaefer Price, Pharmasset's Chief Executive Officer, will provide an overview of the company on Wednesday, June 11, 2008 from 9:00 AM to 9:30 AM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Kurt Leutzinger

Chief Financial Officer

kurt.leutzinger@pharmasset.com

Office: +1 (609) 613-4110


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
3. Pharmasset Accesses up to $30 Million of Working Capital
4. Pharmasset to Present at Three Investor Conferences in November 2007
5. Pharmasset Appoints Michael Rogers as Chief Development Officer
6. Pharmasset Reports Fiscal Year End 2007 Financial Results
7. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
8. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
9. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
10. Pharmasset Appoints Herbert J. Conrad as a Director
11. Pharmasset Receives $10 Million of Working Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 A Europe-wide survey of ... researchers using animals in their research treat them with due care. ... and detailed analysis of the results indicates that there is a ... to put into practice the principles of the 3Rs (Refine, ... What ...
(Date:2/27/2017)... , Feb. 27, 2017 Fluxion Biosciences announced ... has been appointed as a Certified Service ... IsoFlux system will be used in Genetracer Biotech,s novel ... lung and colon cancer, with plans to move to ... is utilizing Fluxion,s IsoFlux System to isolate, recover, and ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... procedures can be safely completed in an ambulatory surgery center (ASC) with satisfactory ... procedures and previous two-year TDR studies. , Jake Lubinski, president of AxioMed, ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):